Biostar Announces $9.6 Million China Acquisition

Biostar Pharmaceuticals will pay 61 million RMB ($9.6 million) in cash to acquire Shaanxi Weinan Huaren Pharmaceuticals, Ltd. For Biostar, the attraction of Shaanxi Weinan is a portfolio of 86 approved drugs and one health product. Shaanxi Weinan reported revenues of $3.3 million in 2009 and $4.4 million in 2010, with net income of at least 15%. More details.... Stock Symbol: (NSDQ: BSPM)     Share this with colleagues: